Hepatology

Latest News

March 2nd 2025

Mortality Declines but Incidence Rates Up for Cirrhosis and Other Chronic Liver Diseases

By Laura Joszt, MA

February 19th 2025

Promising Potential for FGF21 Analogs in MASH Management

February 6th 2025

MASH-Related PLC on the Rise in Young Adults

January 28th 2025

"Alarming Rise" of Global MASH-Related Primary Liver Cancer Incidence Since 2000

January 20th 2025

A Potential Early Biomarker for MASLD: Oxidized Apolipoproteins

More News

Top 5 liver cancer content of 2024 image graphic with health icons

December 27th 2024

Top 5 Most-Viewed Liver Cancer Content for 2024

Laura Joszt, MA

Advances in therapy are improving outcomes for patients, but the incidence and mortality rates for hepatocellular carcinoma are increasing in the US.

Doctor with human liver anatomy model | Image credit: Jo Panuwat D - stock.adobe.com

December 1st 2024

Tislelizumab Pushes HCC Field Forward With 2024 NCCN Guideline Category 1 Recommendation

Tislelizumab's inclusion in the National Comprehensive Cancer Network (NCCN) guidelines for hepatocellular carcinoma (HCC) as a category 1 recommendation marks an advancement in the treatment landscape for HCC.

Man holding liver illustration - SewcreamStudio - stock.adobe.com

November 26th 2024

Patients With HCC May Avoid Additional Treatment After Complete Response

Laura Joszt, MA

Patients with locally advanced hepatocellular carcinoma (HCC) who achieve a complete response after locoregional therapy and immunotherapy may be able to follow a watch-and-wait protocol.

Paper liver with a stethoscope | Image credit: filins - stock.adobe.com

November 24th 2024

Real-World Results of Durvalumab/Tremelimumab in U-HCC Show Promise Despite Line of Therapy

Laura Joszt, MA

Patients experienced similar safety and efficacy if they received first-line or later-line treatment for unresectable hepatocellular carcinoma (u-HCC).

Man holding liver illustration - SewcreamStudio - stock.adobe.com

June 12th 2024

Study Highlights Increasing Global Health Burden of Liver Cancer

The global burden of liver cancer is rising, and public health efforts for prevention, vaccination, and treatment to address underlying etiologies are needed, according to research presented at ASCO 2024.

doctor checking liver

October 11th 2022

ICER to Assess Clinical Effectiveness, Value of 2 NASH Treatments

Laura Joszt, MA

There are no FDA-approved therapies for nonalcoholic steatohepatitis (NASH), but there are many being developed. Resmetirom and obeticholic acid are both being reviewed by the FDA with decisions expected in 2023.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions